Cargando…
Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study
BACKGROUND: Glatiramer acetate (GA) is US-approved for relapsing multiple sclerosis. OBJECTIVES: To describe GA long-term clinical profile. To compare effectiveness of early start (ES) versus delayed start (DS; up to 3 years) with GA. METHODS: Phase 3 trial participants entered a randomized placebo-...
Autores principales: | Ford, Corey C, Cohen, Jeffrey A, Goodman, Andrew D, Lindsey, John W, Lisak, Robert P, Luzzio, Christopher, Pruitt, Amy, Rose, John, Rus, Horea, Wolinsky, Jerry S, Kadosh, Shaul E, Bernstein-Hanlon, Emily, Stark, Yafit, Alexander, Jessica K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442630/ https://www.ncbi.nlm.nih.gov/pubmed/35768939 http://dx.doi.org/10.1177/13524585221094239 |
Ejemplares similares
-
Continuous long-term immunomodulatory therapy in relapsing multiple
sclerosis: results from the 15-year analysis of the US prospective open-label
study of glatiramer acetate
por: Ford, C, et al.
Publicado: (2010) -
Long-term efficacy and safety of three times weekly dosing regimen of glatiramer acetate in relapsing multiple sclerosis patients: Seven-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension study
por: Rieckmann, Peter, et al.
Publicado: (2021) -
Glatiramer acetate in the treatment of multiple sclerosis
por: Tselis, Alex, et al.
Publicado: (2007) -
Follow-on glatiramer acetate
por: Cohen, Jeffrey A., et al.
Publicado: (2018) -
Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies
por: Izquierdo, Guillermo, et al.
Publicado: (2015)